Proteomics

Dataset Information

0

LC7 Proteomic Analysis of Matched Control and NSCLC Lung Adenocarcinoma Tissue.

ABSTRACT: Non-small cell lung adenocarcinoma is the most frequently diagnosed lung cancer type and remains the leading cause of cancer mortality for men and women in the United States. Management of lung cancer is hindered by high false-positive rates due to the inability to resolve benign versus malignant tumors. Therefore, better molecular analysis comparing malignant and non-malignant tissues will provide additional evidence of the underlying biology contributing to tumorigenesis. In the current study, we utilized a proteomics approach to analyze 38 malignant and non-malignant paired tissue samples obtained from current or former smokers with early stage (Stage IA/IB) lung adenocarcinoma. Statistical mixed effects modeling and orthogonal partial least squares discriminant analysis were used to identify key cancer-associated perturbations in the malignant tissue proteome. Identified proteins were subsequently assessed against clinicopathological variables.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung

DISEASE(S): Non-small Cell Lung Carcinoma

SUBMITTER: Brett Phinney  

LAB HEAD: Suzanne Miyamoto

PROVIDER: PXD002612 | Pride | 2016-12-23

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.

Fahrmann Johannes F JF   Grapov Dmitry D   Phinney Brett S BS   Stroble Carol C   DeFelice Brian C BC   Rom William W   Gandara David R DR   Zhang Yanhong Y   Fiehn Oliver O   Pass Harvey H   Miyamoto Suzanne S  

Clinical proteomics 20161027

<h4>Background</h4>Lung cancer is the leading cause of cancer mortality in the United States. Non-small cell lung cancer accounts for 85% of all lung cancers for which adenocarcinoma is the most common histological type. Management of lung cancer is hindered by high false-positive rates due to difficulty resolving between benign and malignant tumors. Better molecular analysis comparing malignant and non-malignant tissues will provide important evidence of the underlying biology contributing to t  ...[more]

Similar Datasets

Proteomics LC7 Proteomic Analysis of Matched Control and NSCLC Lung Adenocarcinoma Tissue.
2017-03-31 | MSV000080825 | MassIVE
Proteomics Characterizing the secretome of EGFR mutant lung adenocarcinoma
2024-01-03 | PXD045328 | Pride
Proteomics Matched Lung Tumor And Emphysematous Matrix Proteomics, Transcriptomics, and Translatomics
2019-05-28 | PXD007919 | Pride
Transcriptomics Whole Genome Exon Arrays Identify Differential Expression of Alternatively Spliced, Cancer-related Genes in Lung Cancer
2008-10-17 | E-GEOD-12236 | biostudies-arrayexpress
Transcriptomics Spheres culture from lung adenocarcinoma pleural effusions
2011-12-02 | E-MEXP-3025 | biostudies-arrayexpress
Models Ito2019 - gefitnib resistance of lung adenocarcinoma caused by MET amplification
2019-09-30 | BIOMD0000000827 | BioModels
Proteomics Quantitative proteomics identifies tumour matrisome signatures in patients with non-small cell lung cancer
2023-06-16 | PXD041066 | Pride
Transcriptomics MicroRNA Expression Profile Reveals Important Clinical Tools for the Pathology of Lung Cancer
2010-02-10 | E-GEOD-15008 | biostudies-arrayexpress
Proteomics VESTIGIAL-LIKE 1 IS A SHARED TARGETABLE CANCER-PLACENTA ANTIGEN EXPRESSED BY PANCREATIC AND BASAL-LIKE BREAST CANCERS
2020-10-19 | PXD018302 | Pride
Proteomics Proteomic changes between primary tumors and matched distant metastases of lung adenocarcinomas
2023-11-28 | PXD042604 | Pride